Guggenheim Maintains Buy on Dyne Therapeutics, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $45 to $50.
August 15, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Dyne Therapeutics and raises the price target from $45 to $50.
The Buy rating and increased price target from a reputable analyst at Guggenheim is likely to positively influence investor sentiment and drive short-term price appreciation for Dyne Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100